Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) have received a consensus rating of “Reduce” from the eight ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and seven have assigned a hold recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $24.00.
Several equities research analysts recently issued reports on the stock. Weiss Ratings cut shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, April 10th. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Wells Fargo & Company restated an “equal weight” rating and issued a $19.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Thursday, May 14th. Jefferies Financial Group restated a “hold” rating and issued a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Finally, Piper Sandler restated a “neutral” rating and issued a $21.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 11th.
View Our Latest Stock Analysis on AMPH
Institutional Investors Weigh In On Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Trading Down 1.9%
Shares of AMPH stock opened at $18.09 on Thursday. Amphastar Pharmaceuticals has a 12-month low of $16.65 and a 12-month high of $31.26. The company has a current ratio of 3.85, a quick ratio of 2.82 and a debt-to-equity ratio of 0.79. The firm’s 50 day moving average is $20.03 and its 200 day moving average is $23.66. The stock has a market capitalization of $797.76 million, a P/E ratio of 10.90, a P/E/G ratio of 3.63 and a beta of 0.91.
Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.28). Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%.The company had revenue of $171.17 million during the quarter, compared to analysts’ expectations of $173.46 million. Research analysts expect that Amphastar Pharmaceuticals will post 2.41 earnings per share for the current year.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.
Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.
Featured Articles
- Five stocks we like better than Amphastar Pharmaceuticals
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
- Palo Alto Networks Accelerates Growth 31% on AI Demand
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
